11. DRUG SUMMARY BOX
Drug Name: NorLeu3-Angiotensin (1-7) |
Phase: Phase II Clinical Trial |
Indication: Acceleration of closure of diabetic foot ulcer |
Pharmacological Description/Mechanism of Action: The mechanisms of action include induction of progenitor proliferation and accelerated vascularization, collagen deposition and re-epithelialization. |
Route of administration: Topical |
Chemical Structure: H2N-Asp-Arg-NorLeu-Tyr-Ile-His-Pro-OH |
Pivotal trial(s): To be initiated |